Ground News

institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

targetedonc.com image

News from targetedonc.com

See all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve aggregated 706 of targetedonc.com’s headlines and news stories over the past 3 months.

Ground News rates targetedonc.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about targetedonc.com

Where is targetedonc.com located?targetedonc.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top targetedonc.com News

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

Johnson & Johnson · United States

With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short

71% Center coverage: 32 sources

Dizal Pharmaceutical’s Zegfrovy is now FDA approved for treating non-small cell lung cancer driven by a particular rare genetic signature. Johnson & Johnson drug Rybrevant already addresses this genetic signature as an earlier line of therapy, but Dizal executives contend their drug offers the potential for better safety and efficacy. The post With FDA Nod in Lung Cancer, Dizal Now Aims to Best a J&J Drug and Succeed Where Takeda Fell Short appe…See the Story

Innovent's Dual Cancer Innovation Platform Shows Breakthrough Results in Clinical Trials

Artificial Intelligence · China

Innovent's Dual Cancer Innovation Platform Shows Breakthrough Results in Clinical Trials

86% Center coverage: 14 sources

Revolutionary IO-ADC combination shows 70% survival rate in resistant cancers. Innovent's dual-platform strategy targets untreatable tumors. See latest trial data.See the Story

New Bispecific T-Cell Engager Approved for Multiple Myeloma

Cancer · United States

New Bispecific T-Cell Engager Approved for Multiple Myeloma

83% Center coverage: 6 sources

(MedPage Today) -- The FDA on Wednesday granted accelerated approval to linvoseltamab (Lynozyfic) for relapsed or refractory multiple myeloma after at least four prior lines of therapy. A B-cell maturation antigen (BCMA)-directed bispecific antibody...See the Story

The Future of Bladder Cancer Care: Can Latest Medical Advances Make a Difference?

New Delhi: With their medical innovations, the researchers have paved the way for advanced treatment options for bladder cancer. From personalised immunotherapies and targeted drug treatment to minimally invasive surgical techniques, the scope of care for bladder cancer patients is rapidly evolving. This article uncovers the latest medical advances that can regain the lost hopes of patients who have bladder cancer and help them discover how mode…See the Story

Current and Future Colorectal Cancer Screening Strategies

100% Center coverage: 2 sources

Despite strong evidence of effectiveness, colorectal cancer (CRC) screening remains underused. Currently, there are several options for CRC screening, each with its own performance characteristics and considerations for practice. This Review aims to cover current CRC screening guidelines and highlight future blood-based and imaging-based options for screening. In current practice, the leading non-invasive option is the faecal immunochemical test…Cancer See the Story

New Colorectal Cancer Therapies: Hope on the Horizon

Anita Turk, MD, discusses what she is most excited about regarding immunotherapy in the realm of colorectal cancer treatment.Cancer · Maryland Read Article

Phase 1 Trial of JBZ-001 Targets Solid Tumors and Non-Hodgkin Lymphoma

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.Read Article

A Look Back to ASCO 2025: Industry Comments From iOnctura and Asgard Therapeutics

100% Center coverage: 1 sources

Here, Michelle Tsai – chief operating officer at iOnctura – and Shane Olwill – chief development officer at Asgard Therapeutics – share their views on the broader cancer care landscape and ponder what’s hyped, what’s not being duly appreciated, and what might be coming next.Maryland · Maryland See the Story

Long-Term Data Validates IsoPSA for Prostate Cancer Risk Stratification

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.Read Article

AI Tool Accurately Predicts Prostate Cancer Outcomes Across Racial Groups

Mack Roach III, MD, discusses the development and evaluation of a multimodal AI algorithm designed to predict prostate cancer outcomes and its performance across racial subgroups.Healthcare See the Story

Dr Jimenez Jimenez on Increasing Transplant Access Through Mismatch Donors

Antonio Jimenez Jimenez, MD, discusses the ACCESS trial of PTCy-based GVHD prophylaxis after mismatched unrelated donor stem cell transplantation.Maryland · Maryland Read Article

Breaking News Topics Related to targetedonc.com